Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 11/20 | 0.57 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31373078 | 0.89 | CCND1 (0.47) | CCND1CDK6BRD4CDK4 | |
| SCHEMBL31373079 | 0.89 | CCND1 (0.47) | CCND1CDK6BRD4CDK4 | |
| SCHEMBL29514933 | 0.81 | CCND1 (0.41) | CCND1CDK6CDK4SMN1; SMN2 | |
| SCHEMBL24322202 | 0.81 | CCND1 (0.41) | CCND1CDK6CDK4SMN1; SMN2 | |
| SCHEMBL29514866 | 0.75 | CCND1 (0.73) | CCND1CDK6CDK4 | |
| SCHEMBL24322957 | 0.75 | CCND1 (0.73) | CCND1CDK6CDK4 | |
| SCHEMBL31257391 | 0.75 | CCND1 (0.58) | CCND1CDK6CDK4 | |
| SCHEMBL24322173 | 0.74 | CCND1 (1.00) | CCND1CDK6CDK4 | |
| SCHEMBL24323632 | 0.73 | CCND1 (0.51) | CCND1CDK6CDK4 | |
| SCHEMBL29515017 | 0.73 | CCND1 (0.51) | CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747261-A1 | AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | Accutar Biotechnology Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12338248-B2 | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250197418-A1 | Polymorphic Compounds And Uses Thereof | PRELUDE THERAPEUTICS INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250084095-A1 | Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors | ACCUTAR BIOTECHNOLOGY INC. | 2025-03-13 | — | — | US | disclosed |
| CN-119421884-A | Polymorphic compounds and uses thereof | 普莱鲁德疗法有限公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2025024388-A1 | AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| EP-4496627-A1 | POLYMORPHIC COMPOUNDS AND USES THEREOF | Prelude Therapeutics Incorporated (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2024220866-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| WO-2023178547-A1 | POLYMORPHIC COMPOUNDS AND USES THEREOF | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023178547-A1 | POLYMORPHIC COMPOUNDS AND USES THEREOF | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-116583283-A | CDK inhibitors and their use as pharmaceuticals | 普莱鲁德疗法有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-4214213-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | Prelude Therapeutics, Incorporated (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338248-B2 | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | CDK6, CDK2, CDK8 | CCND1 51/4885CDK6 1/4885BRD4 514/4885 |
| US-20250084095-A1 | Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors | CDK6, CDK2, CDK8 | CCND1 51/4885CDK6 1/4885BRD4 514/4885 |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CCND1 46/4885CDK6 1/4885BRD4 738/4885 |
| US-20250197418-A1 | Polymorphic Compounds And Uses Thereof | CDK6, CDK4, CDK8 | CCND1 69/4885CDK6 1/4885BRD4 84/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | CCND1 46/4885CDK6 1/4885BRD4 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.